Brian Leyland-Jones

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi Recommendations for collection and handling of specimens from group breast cancer clinical trials
    Brian R Leyland-Jones
    Emory University School of Medicine, Atlanta, GA 30322, USA
    J Clin Oncol 26:5638-44. 2008
  2. ncbi Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA
    J Clin Oncol 27:5278-86. 2009
  3. ncbi Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University, School of Medicine, 1365C Clifton Rd NE, Ste 4014, Atlanta, GA 30322, USA
    J Clin Oncol 28:960-6. 2010
  4. ncbi Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
    Brian Leyland-Jones
    Emory Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Lancet Oncol 12:286-95. 2011
  5. ncbi Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
    Mary Jo Lund
    Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA
    Breast Cancer Res Treat 113:357-70. 2009

Detail Information

Publications5

  1. ncbi Recommendations for collection and handling of specimens from group breast cancer clinical trials
    Brian R Leyland-Jones
    Emory University School of Medicine, Atlanta, GA 30322, USA
    J Clin Oncol 26:5638-44. 2008
    ..Recommendations for proper handling and shipping were developed for blood, serum, plasma, FFPE, and fresh/frozen tissue...
  2. ncbi Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA
    J Clin Oncol 27:5278-86. 2009
    ..To determine the incidence, outcomes, and current strategies for management of brain metastases in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer...
  3. ncbi Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated
    Brian Leyland-Jones
    Winship Cancer Institute, Emory University, School of Medicine, 1365C Clifton Rd NE, Ste 4014, Atlanta, GA 30322, USA
    J Clin Oncol 28:960-6. 2010
    ..7 months (in all patients). CONCLUSION An intensive loading regimen of trastuzumab achieved higher-than-steady-state serum concentrations during cycle 1, was well tolerated, and had a good efficacy profile...
  4. ncbi Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
    Brian Leyland-Jones
    Emory Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Lancet Oncol 12:286-95. 2011
    ..Furthermore, oncologists should continue to use clinical parameters when making decisions about initiation, continuation, and discontinuation of HER2-targeted treatments...
  5. ncbi Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
    Mary Jo Lund
    Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA
    Breast Cancer Res Treat 113:357-70. 2009
    ..This study examines association of the ER/PR/HER2 subtypes with race and breast cancer survival...